



ANDA 208431

ANDA APPROVAL

Mylan Pharmaceuticals, Inc.
Attention: Beth Britton
Head of Regulatory Affairs, US Generics

Dear Beth Britton:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on May 4, 2015, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Linagliptin Tablets, 5 mg.

Reference is also made to the tentative approval letter issued by this office on November 3, 2017, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Linagliptin Tablets, 5 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tradjenta Tablets, 5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer) NDA - 201280.

The RLD upon which you have based your ANDA, Boehringer's Tradjenta Tablets, 5 mg, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
8,673,927 (the '927 patent)	November 4, 2027*
8,846,695 (the '695 patent)	December 4, 2030*
8,853,156 (the '156 patent)	September 5, 2031*
8,883,805 (the '805 patent)	May 26, 2026*
9,486,526 (the '526 patent)	February 5, 2030*
10,034,877 (the '877 patent)	February 5, 2030*

11,033,552 (the '552 patent)	November 4, 2027*
11,911,388 (the '388 patent)	April 10, 2030
12,178,819 (the '819 patent)	May 4, 2027
12,364,700 (the '700 patent)	December 8, 2037*

* with pediatric exclusivity added

Your ANDA contains paragraph IV certifications to the '156, '805, '526, '877, '552, '388, '819 and '700 patents, under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Linagliptin Tablets, 5 mg, under this ANDA. You have notified the Agency that Mylan Pharmaceuticals, Inc. (Mylan) complied with the requirements of section 505(j)(2)(B) of the FD&C Act. Litigation was initiated within the statutory 45-day period against Mylan for infringement of the '156 patent in the United States District Court for the District of New Jersey [Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GMBH, Boehringer Ingelheim Corporation, and Boehringer Ingelheim Pharma GMBH & Co. KG v. Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited, Civil Action No. 15-05982]. You have also notified the Agency that this case was dismissed.

With respect to the '927 and '695 patents, your ANDA contains statements under section 505(j)(2)(A)(viii) of the FD&C Act that these are method-of-use patents that do not claim any indication or other conditions of use for which you are seeking approval under your ANDA.

With respect to 180-day generic drug exclusivity, we note that Mylan was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Linagliptin Tablets, 5 mg. Therefore, with this approval, Mylan is eligible for 180 days of shared generic drug exclusivity for Linagliptin Tablets, 5 mg. FDA notes that after issuance of this approval letter, eligibility for 180-day exclusivity is subject to future events that may result in forfeiture of exclusivity under section 505(j)(5)(D) of the FD&C Act. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, begins to run from the date of the commercial marketing by any first applicant, as identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as <https://www.uspnf.com/>.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

{See appended electronic signature page}

For Kendra S. Stewart, R.Ph., Pharm.D.
CAPT, United States Public Health Service
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Paul
Levine

Digitally signed by Paul Levine
Date: 11/03/2025 02:53:29PM
GUID: 56323ddc003554a87fad6698c2baa467